D A comparative study of omeprazole and lansoprazole in the short-term treatment of reflux esophagitis showed no significant difference in healing after 4 or 8 weeks. Lansoprazole, however, showed greater improvement in heartburn and acid regurgitation symptoms after 4 weeks. D Lansoprazole has also been demonstrated to be safe and effective for chronic therapy of Zollinger-Ellison syndromeD and for Barrett's esophagus. D Lansoprazole was approved by the FDA in May 1995. It currently is not approved for maintenance therapy of esophagitis or duodenal ulcers.
Lansoprazole inhibits gastric acid secretion.
A significant increase in gastric pH and decrease in basal acid output follow oral administration of lansoprazole. Lansoprazole exerts an inhibitory effect on gastric acid for at least 24 hours, which allows a once-daily dosing schedule. Lansoprazole does not antagonize HA or cholinergic receptors. D Increases reach a plateau within 2 months and return to pretreatment levels within 4 weeks of discontinuation of lansoprazole therapy. Both patients already had extensive metastatic disease.